Table 2.
Response, location of primary disease, prior therapy, and duration of therapy (days).
| Enrolled patient ID No. | Response | Primary site of disease | Prior chemotherapy regimens | Duration of therapy (days) |
|---|---|---|---|---|
| 1 | PD | Colon and duodenum | Dox | 34 |
| 2 | PD | Uterus | Dox/taxotere; Ifos/DTIC/etoposide; gleevec | 16 |
| 3 | PD | Uterus | Dox/ifex; gem/taxotere | 37 |
| 4 | PD | Stomach | Gleevec; ifex/dox | 8 |
| 5 | PD | Retroperitoneal | Doxil; ifos; taxotere/gem; digitoxin | 25 |
| 6 | SD | Unknown | Dox/ifex | *114/398 |
| 7 | PD | Iliopsoas | Dox; gem/taxotere | 42 |
| 8 | PR | Retroperitoneal | None | *382/389 |
| 9 | PD | Ovarian | Doxo/ifex; gem/taxotere | 45 |
| 10 | PD | Uterus | Doxil, gem | 62 |
| 11 | PD | Uterus | Gem/taxotere | 56 |
| 12 | PD | Pelvic mass | Gem/taxotere | *36/62 |
| 13 | PR | Uterus | Dox/ifos; gem/taxotere | 670 |
| 14 | PD | Unknown | DTIC/doxo; gem/taxotere; digitoxin; ifos | 50 |
| 15 | SD | Uterus | Dox/ifox/taxotere | 186 |
| 16 | PD | Uterus | Gem/taxotere | 52 |
| 17 | SD | Uterus | Dox; gem; taxotere | 143 |
| 18 | SD | Uterus | None | *157/207 |
| 19 | PD | Colon | None | 37 |
| 20 | PD | Uterus | Ifos; gem | *30/53 |
| 21 | PD | Kidney | None | 78 |
| 22 | PD | Small bowel | Dox/avastin; gem; DTIC | 53 |
| 23 | SD | Retroperitoneal | MAID; vin/doxo/cytoxan | 383 |
| 24 | PD | Uterus | Gem/taxotere | 36 |
*For the 5 patients who discontinued thalidomide early, the fraction represents duration of therapy in days for Temodar + Thalidomide over total days of therapy with Temodar.